A recombinant virus assay using full-length envelope sequences to detect changes in HIV-1 co-receptor usage

Virus Genes

Volumn 23, Issue 3, 2001, Pages 281-290

  Dittmar, M T ^a,b   Eichler, S ^a,b   Reinberger, S ^a,b   Henning, L ^a,b   Krausslich H G ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

Recombinant virus assay; Resistance; Viral phenotype

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; VIRUS RECEPTOR;

ARTICLE; ASSAY; CONTROLLED STUDY; ENVELOPE GENE; GENE AMPLIFICATION; GENE CONSTRUCT; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL ASSAY; CELL LINE; DRUG RESISTANCE, VIRAL; ELECTROPORATION; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LYMPHOCYTES; MICROBIOLOGICAL TECHNIQUES; PHENOTYPE; RECEPTORS, HIV; RECOMBINATION, GENETIC; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0035213701     PISSN: 09208569     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012569206007     Document Type: Article

References (50)

1. Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, suppression and resistance
2. Incidence and impact of resistance against approved antiretroviral drugs
3. A Advances in the medical management of patients with HIV-1 infection: An overview
4. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
5. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study
6. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
7. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain
8. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
9. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
10. HIV-1 entry inhibitors in the side pocket
11. HIV entry and its inhibition
12. Immunodeficiency viruses. Spoilt for choice of co-receptors
13. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1)
14. Coreceptors: Implications for HIV pathogenesis and therapy
15. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
16. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure
17. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
18. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
19. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
20. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity
21. Chemokines and viruses: The dearest enemies
22. Current evidence and future directions for targeting HIV entry: Therapeutic and prophylactic strategies
23. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
24. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
25. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket
26. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides
27. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1
28. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
29. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage
30. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
31. The U3 promoter region of the acutely lethal simian immunodeficiency virus clone smmPBj1.9 confers related biological activity on the apathogenic clone agm3mc
32. Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long-range PCR
33. Electric shock-mediated transfection of cells. Characterization and optimization of electrical parameters
34. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
35. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity
36. Coreceptor requirements of primary HIV type 1 group O isolates from Cameroon
37. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus
38. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay
39. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay
40. Expanded tropism of primary human immunodeficiency virus type 1 R5 strains to CD4(+) T-cell lines determined by the capacity to exploit low concentrations of CCR5
41. Host range mutant of human immunodeficiency virus type 1: Modification of cell tropism by a single point mutation at the neutralization epitope in the env gene
42. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism
43. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1
44. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies
45. Loss of a Single N-Linked Glycan Allows CD4-Independent Human Immunodeficiency Virus Type 1 infection by Altering the Position of the gp120 V1/V2 Variable Loops
46. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion
47. Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity
48. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants
49. Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction
50. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients